Johnson & Johnson (JNJ) reported strong second-quarter earnings, surpassing estimates for both revenue and profit. The company's revenue reached $22.45 billion, exceeding the expected $22.34 billion, while adjusted earnings per share hit $2.82, above the projected $2.71 per share. JNJ CFO Joe Wolk sits down with Yahoo Finance health reporter Anjalee Khemlani to discuss the pharma giant's new products and growth strategies.
Wolk highlights the company's research and development (R&D) efforts, detailing plans to expand the use cases for its antibody Tremfya, including Crohn's disease. Additionally, Wolk discusses the upcoming launch of Rybrevant to treat lung cancer: "That's an area we think we can have a profound impact."
"We have at least ten products or platforms that will be $5 billion in peak year sales over the near term," Wolk tells Yahoo Finance, emphasizing the company's robust product pipeline and growth potential.
For more expert insight and the latest market action, click here to watch this full episode of Catalysts.
This post was written by Angel Smith